secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K/A
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0001104659-23-027339
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma discloses separation terms for departing CFO Andrew Hindman
--------------------------------------------------------------------------------

- Separation agreement includes lump sum of 24 weeks base salary and 100% of 2022 target cash bonus.
- Company to pay up to 9 months COBRA premiums.
- 20,000 performance-based RSUs vested (performance criteria met).
- Hindman eligible for change in control severance if change in control within 3 months after Dec 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923027339/0001104659-23-027339-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923027339/tm238017d4_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-027339

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer